Serious adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events · people with active UC
Antibiotics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review